Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Betting On Biosimilars In China? Think Again

This article was originally published in PharmAsia News

Executive Summary

Interchangeability, reimbursement, approval delays: as the issues keep piling up, will biosimilars offer attractive opportunities for pharma firms in China? Executives from front-running biotechs and legal experts shared their views at a recent meeting in Shanghai.

You may also be interested in...



Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap

Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.

Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap

Perhaps encouraged by the recent successful initial public offering of Innovent Bio, more biologics developers in China are turning towards innovative biologics and away from traditional biosimilars.

Invitation Extended: New Chinese Policies Aim To Lure Foreign Pharma Firms

In their latest charm offensive, Chinese regulators issue policies clearly designed to encourage the import of innovative drugs from overseas and better serve foreign drug makers already operating in the country.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC088818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel